BK-NM-AMT, or βk-NM-αMT, also known as β-keto-N-methyl-αMT or α,N-dimethyl-β-ketotryptamine, as well as 3-indoylmethcathinone, is a serotonin–dopamine releasing agent (SDRA) and putative entactogen of the tryptamine, α-alkyltryptamine, and β-ketotryptamine families.
Pharmacology Pharmacodynamics BK-NM-AMT acts as a serotonin–dopamine releasing agent (SDRA). The values of BK-NM-AMT for monoamine release are 41.3nM for serotonin and 92.8nM for dopamine in rat brain synaptosomes, whereas it only induced 55% release of norepinephrine at a concentration of 10μM. Along with certain other tryptamines, such as α-ethyltryptamine (αET), 5-chloro-αMT and 5-fluoro-αET, it is one of the few SDRAs known.
+ Monoamine release of BK-NM-AMT and related compounds (, nM) Compound Type Ref Tryptamine 32.6 716 164 SDRA α-Methyltryptamine (αMT) 21.7–68 79–112 78.6–180 SNDRA 5-Fluoro-αMT 19 126 32 SNDRA 5-Chloro-αMT 16 3434 54 SDRA BK-NM-AMT 41.3 (55% at 10μM) 92.8 SDRA BK-5F-NM-AMT 190 620 BK-5Cl-NM-AMT 200 865 BK-5Br-NM-AMT 295 2100 Notes: The smaller the value, the more strongly the substance releases the neurotransmitter. The assays were done in rat brain synaptosomes and human potencies may be different. See also Monoamine releasing agent § Activity profiles for a larger table with more compounds.
Chemistry BK-NM-AMT, also known as β-keto-N-methyl-α-methyltryptamine, is the N-methyl and β-keto derivative of α-methyltryptamine (αMT). It is a cathinone-like tryptamine and can be thought of as the tryptamine or indole analogue of the phenethylamine methcathinone (β-keto-N-methylamphetamine).
Analogues Analogues of BK-NM-AMT include α-methyltryptamine (AMT) and α,N-dimethyltryptamine (α,N-DMT; NM-AMT), among others.
Derivatives Several 5-halogenated derivatives of BK-NM-AMT have also been described. These include BK-5F-NM-AMT, BK-5Cl-NM-AMT, and BK-5Br-NM-AMT. Like BK-NM-AMT, they induce serotonin and dopamine release. In contrast to many other tryptamines however, these novel β-keto-substituted tryptamine derivatives are inactive as agonists of serotonin receptors including the 5-HT1, 5-HT2, and 5-HT3 receptors. In addition, unlike other α-alkyltryptamines like αMT, these compounds are inactive as monoamine oxidase inhibitors (MAOIs).
History BK-NM-AMT and its 5-halogenated analogues were patented by Matthew Baggott and Tactogen in late 2024.
See also Substituted α-alkyltryptamine Substituted β-ketotryptamine 1Z2MAP1O and 1ZP2MA Serotonin–dopamine releasing agent § Examples of SDRAs
References
External links β-Oxo-α-methyl-NMT - Isomer Design